Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.

Original languageEnglish
Pages (from-to)33-43
Number of pages11
JournalJournal of Parkinson's Disease
Volume8
Issue number1
DOIs
Publication statusPublished - 18 Feb 2018

Fingerprint

alpha-Synuclein
Parkinson Disease
Advanced Glycosylation End Products
Proteins
Diabetes Complications
Drug Delivery Systems
Neurodegenerative Diseases
Pathology
Mutation
Genes

Keywords

  • Glycation
  • Maillard-reaction
  • Parkinson’s disease
  • alpha-synuclein

Cite this

@article{7138ee80d65f49d78e339ba0faa071b3,
title = "Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease",
abstract = "Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.",
keywords = "Glycation, Maillard-reaction, Parkinson’s disease, alpha-synuclein",
author = "Annekatrin K{\"o}nig and {Vicente Miranda}, Hugo and Outeiro, {Tiago Fleming}",
year = "2018",
month = "2",
day = "18",
doi = "10.3233/JPD-171285",
language = "English",
volume = "8",
pages = "33--43",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "1",

}

Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. / König, Annekatrin; Vicente Miranda, Hugo; Outeiro, Tiago Fleming.

In: Journal of Parkinson's Disease, Vol. 8, No. 1, 18.02.2018, p. 33-43.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease

AU - König, Annekatrin

AU - Vicente Miranda, Hugo

AU - Outeiro, Tiago Fleming

PY - 2018/2/18

Y1 - 2018/2/18

N2 - Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.

AB - Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.

KW - Glycation

KW - Maillard-reaction

KW - Parkinson’s disease

KW - alpha-synuclein

U2 - 10.3233/JPD-171285

DO - 10.3233/JPD-171285

M3 - Review article

VL - 8

SP - 33

EP - 43

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 1

ER -